Synovial sarcoma X breakpoint 1 (SSX1)

Synovial sarcoma X breakpoint 1 (SSX1) is a member of the cancer-testis antigen (CTA) family, characterized by its restricted expression in the testis and aberrant expression in various malignant tissues (UniProt: Q16384). It plays a critical role in the pathogenesis of synovial sarcoma through a characteristic t(X;18)(p11;q11) chromosomal translocation, which creates the SS18-SSX1 fusion protein (NCBI Gene: 6756). This fusion protein functions as a potent oncogenic driver by interacting with and dysregulating the BAF (SWI/SNF) chromatin-remodeling complex, leading to global epigenetic changes and altered gene expression (PMID: 30224515). Due to its tumor-specific expression pattern, SSX1 is a high-priority target for immunotherapeutic interventions, including T-cell receptor (TCR) engineered T-cell therapies and cancer vaccines designed to elicit a cytotoxic T-lymphocyte response (PMID: 24631835). Beyond immunotherapy, research is focused on developing strategies to degrade the SS18-SSX1 fusion protein or inhibit its recruitment to chromatin. The detection of the SS18-SSX1 fusion transcript remains the definitive diagnostic biomarker for synovial sarcoma and is essential for patient selection in clinical trials targeting this pathway.

Other names

Protein SSX1Cancer/testis antigen 5.1CT5.1SXY1

T-cell mediated cytotoxicity directed against SSX1-derived peptides presented on MHC class I molecules; disruption of the oncogenic SS18-SSX1 fusion protein complex.